Bioquimico

1-
4-
5-
9-
11-
12-
13-Melvin J. Silverstein.: Ductal Carcinoma in Situ of breast A Surgeon's Disease. Ann Surg Oncol 1999;6:802-810
14-
15-Luz A. Venta and Lori Ann Goodhartz.: Age and Interval for Screening Mammography: Whom Do You Believe Seminars Surg oncolog 1996; 12(5):281-290
16-
17-
18-Steve Parker and Melvin J Silverstein.: Ductal Carcinoma in Situ (DCIS) of the Breast:Diagnostic and Therapeutic Controversies J Am Coll Surg 2001; 192(2):196-214
19-Vanzee KJ et al.: Long term follow up of women with ductal carcinoma in situ treated with breast conserving surgery. 1999;96:1757-67.
20-Kestins L.: Factors associated with loca recurrencia of mamographically detected ductal carcinoma in situ in patients given breast conserving therapy. Cancer 2000;88:596-607.
21-VanDiest PJ., Van der Wall E., Baak JP.: Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol, 2004; 57: 675/81.
22-
24-
25-
26-
27-
38-Otterbach F, Bànkfalvi A, Bergner S, Decker T, Krech R, Boecker W.: Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology. 2000 Sep;37(3):232-40.
39-
44-45-
51-De Armas Pereira R.: Estudio de mediadores lipídicos en la patología de meningiomas y gliomas. 2010. University of Limoges
52-

1-Robbins., Cotran., Kumar V., Abbas AK., Fausto N.: Patología estructural y funcional. 2005; 7a edición. 1124-1128 .
2-Shackleton M., Vaillant F., Simpson KJ., et al: Generation of a functional mammary gland from a single stem cell. Nature. 2006; 439:84–88.3-Stingl J., Eirew P., Ricketson I., et al: Purification and unique properties of mammary epithelial stem cells. Nature. 2006;439:993–997.
4-Rosen PP., Harold AO.: Tumors of the Mammary Gland. 3°edicion, fasciculo 7; editorial AFIP, 1992; 11-13
5-Rosai J.: Surgical Patholog. 8°edition volume 2, Editoria Mosby, 1995 ; 1565-1568.
6-Burstein HJ, Harris JR, Morrow M. Malignant tumors of thebreast. Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008:1606–1654.
7-Muse I. , Masetti D. , Sosa M. A. , Hinojosa L. S. y Terradas M. L. Manual De Oncología Para El Primer Nivel De Atención ; 2004:10-12.
8-Clasificación del carcinoma mamario de la OMS (2008)
9-Mark S Talamonti.: Management of ductal carcinoma in situ. Seminars Surg Oncol 1996;12:300-313.
10-Michael D. Lagios.: Carcinoma Ductal in Situ: clasificación, inferencias biológicas y resultados clínicos. Focus 2000; 10: 33-46
11-Mark S Talamonti.: Management of ductal carcinoma in situ. Seminars Surg Oncol 1996; 12:300-313.
12-De Vita Vincent T.: Cancer Principles and Practice of Oncology 5° Edición. Lippincot-Raven, 1997.
13-Foote FW J., Stewart FW.: Lobular carcinoma insitu: A rare form of mammary carcinoma. Am JPathol 1992; 17: 491-99
14-López Valle M. A., Uriban Aguilar Gallegos, Dulce María Albertina Camarena Cabrera. Carcinoma lobulillar infiltrante de mama: etapa clínica, características radiológicas e histológicas. Ginecol Obstet Mex 2005;73:629-36.
15-Jensen E., Cheng G., Palmieri C., Saji S., Makela S., Van Noorden S., Wahlstrom V., Warner W.,Coombes RC., Gustafsson JA.: Estrogen receptors and proliferation markers in primary and recurrent breast cancer. PNAS. 2001; vol. 98. no. 26. 15197– 15202.
16-Sommer S, Fuqua SA.: Estrogen receptor and breast cancer. Semin Cancer Biol. 2001 Oct;11(5):339-52.
17-Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh le D, To TV, Qian Z, Love RR, Allred DC.: Progesterone receptor byimmunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004 Dec;17(12):1545-54.
18-Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993;7:1244–1255.
19-Xiuhua Gao and Zafar Nawaz.: Progesterone receptors - animal...